This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Allergic reactions
  • /
  • Predictors of response to omalizumab and relapse i...

Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.

Read time: 1 mins
Published:19th Nov 2018
Author: Marzano AV, Genovese G, Casazza G, Fierro MT, Dapavo P, Crimi N et al.
Availability: Pay for access, or by subscription
Ref.:J Eur Acad Dermatol Venereol. 2018.

Chronic spontaneous urticaria (CSU) is defined as spontaneous occurrence of wheals and/or angioedema for ≥6 weeks. Omalizumab is a monoclonal anti?IgE antibody effective in refractory CSU, but its mechanism of action and markers predictive of response remain not completely defined.

Objectives: To correlate baseline levels of two proposed biomarkers, total IgE (bIgE) and d?dimer (bd?dimer), and clinical parameters to omalizumab response and to relapses after drug withdrawal.

Methods: In this retrospective Italian multicentre study, clinical data were collected in 470 CSU patients, and bIgE and bd?dimer were measured in 340 and 342 patients, respectively. Disease activity was determined by Urticaria Activity Score 7 (UAS7) at week 1 and 12 after omalizumab starting. Relapses were evaluated during a 2? and 3?month interval after a first and a second course of treatment, respectively.

Results: bIgE correlated to a good response to omalizumab since levels were significantly higher in responders than non?responders (P = 0.0002). Conversely, bd?dimer did not correlate to response. There was no correlation between both bIgE and d?dimer and either first or second relapse. Disease duration was significantly longer in patients who experienced either first or second relapse (P < 0.0001 and P = 0.0105, respectively), while baseline UAS7 correlated only to first relapse (P = 0.0023).

Conclusions: Our study confirms bIgE as a reliable biomarker predicting response to omalizumab in CSU, while it does not support the usefulness of bd?dimer unlike previous findings. CSU duration before omalizumab and baseline UAS7 may be clinical markers of relapse risk.


Read abstract on library site

Access full article